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S U M M A R Y
Background: Bacterial brain abscesses remain a serious central nervous system problem despite
advances in neurosurgical, neuroimaging, and microbiological techniques and the availability of new
antibiotics. The successful treatment of brain abscesses requires surgery, appropriate antibiotic therapy,
and eradication of the primary source; nevertheless many controversial issues on the management of
this serious infection remain unresolved.
Controversial issues: The aim of this GISIG (Gruppo Italiano di Studio sulle Infezioni Gravi) working group
– a panel of multidisciplinary experts – was to deﬁne recommendations for some controversial issues
using an evidence-based and analytical approach. The controversial issueswere: (1)Which patientswith
bacterial brain abscesses can bemanaged safely usingmedical treatment alone? (1a)What is the efﬁcacy
in terms of outcome, tolerability, cost/efﬁcacy, and quality of life of the different antibiotic regimens used
to treat bacterial cerebral abscesses? (1b) Which antibiotics have the best pharmacokinetics and/or
tissue penetration of brain and/or brain abscess? 2) What is the best surgical approach in terms of
outcome in managing bacterial brain abscesses? Results are presented and discussed in detail.
Methods: A systematic literature search using the MEDLINE database for the period 1988 to 2008 of
randomized controlled trials and/or non-randomized studies was performed. A matrix was created to
extract evidence from original studies using the CONSORTmethod to evaluate randomized clinical trials
and the Newcastle–Ottawa Quality Assessment Scale for case–control studies, longitudinal cohorts, and
retrospective studies. The GRADE method for grading quality of evidence and strength of
recommendation was applied.
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Brain abscesses are focal suppurative processes in the brain
parenchyma. They begin as localized areas of cerebritis and
develop into a collection of pus surrounded by a well-vascularized
capsule within approximately 14 days.1
Brain abscesses may have ‘exogenous origins’ when lesions are
causedbyskull traumaor surgeryor ‘endogenousorigins’when they
originate from infections of the continuous structures (e.g., otitis
media, sinusitis, mastoiditis, dental infections), meningitis, or as ases. Published by Elsevier Ltd. All rights reserved.
Figure 1. Studies included in the ﬁnal analysis.
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endocarditis, cyanotic congenital heart diseases, pulmonary infec-
tions). Sometimes the origin of the abscess is not found and it
remainsof ‘unknownorigin’. Clinical signsofbrainabscessesdepend
on their origin and location. The most frequent symptoms include
headache, nausea and vomiting, focal neurological deﬁcits, mental
alteration, and fever. The symptoms of infections are not obvious
and fever is not always present, occurring in 24–70% of cases.2,3
Despite modern neuro-imaging and neurosurgical techniques,
including stereotactic brain biopsy and aspiration, better culture
techniques, and new antibiotics, brain abscesses remain a serious
central nervous system (CNS) problem, which can cause severe
disability or even death, especially if misdiagnosed or managed
improperly.4–6 The successful treatment of brain abscesses
requires surgery, appropriate antibiotic therapy, and eradication
of the primary source. Surgical management aims to quickly
reduce increased intracranial pressure, conﬁrm diagnosis, and
obtain pus for microbiological diagnosis in order to enhance the
efﬁcacy of antibiotic therapy and to avoid iatrogenic spread of the
infection into the ventricles.7
However, total recovery using medical treatment alone is
possible in selected patients with brain abscesses,2,6,8 and this
option is very attractive in many cases. Antibiotics are always
necessary to manage cerebral abscesses, either alone or associated
with surgical intervention. In most cases, antibiotics will be
commenced before the infecting organism(s) and their sensitivities
areknown,andarecontinuedeitherempiricallyoronthebasisof the
sensitivity proﬁle of the infecting organism for a long period of time.
Therefore, an ‘ideal’ antibiotic regimen should include anti-
biotics active against the suspected or proven infecting ﬂora, which
can penetrate the brain tissue and intracranial pus with a good
long-term safety proﬁle and be administrable both intravenously
and orally.
There are presently no guidelines for the management of
cerebral abscesses and many controversial issues remain unre-
solved, including the selection of patients who can be treated
conservatively, the best surgical approach, the most appropriate
antibiotic regimens in terms of drug choice, route and time of
administration, the role of new antibiotics, the efﬁcacy of local
administration of antibiotics, the role of antibiotic prophylaxis, and
the appropriate use of corticosteroid therapy.
From these controversial issues, we have tried to formulate
speciﬁc research questions regarding patients who can be treated
solely with medical treatment, the choice of the most effective
antibiotic regimens in terms of activity and penetration of the
brain tissue, and the best choice of surgery.
2. Objectives
To ﬁnd the effects (both detrimental and beneﬁcial), from the
best available evidence, of different management strategies in
patients with cerebral abscesses.
3. Methods
3.1. Controversial issues
The Gruppo Italiano di Studio sulle Infezioni Gravi (GISIG) is a
nationwide group of Italian experts on the diagnostic and
therapeutic management of patients affected by serious health-
care-associated infections. Six expertswere selected on the basis of
their personal curricula to take part in the GISIG working group on
central nervous system (CNS) infections. Among CNS infections the
panel chose to consider the brain abscess. Subsequently, during
twoworkshopmeetings held inMilan, Italy, the panel restricted its
work to the four following controversial issues:Question 1: Which patients with bacterial brain abscesses can
be managed safely using only medical treatment?
Question 1a: What is the efﬁcacy in terms of outcome,
tolerability, cost/efﬁciency, and quality of life of the different
antibiotic regimens used to treat bacterial cerebral abscesses?
Question 1b:Which antibiotics have the best pharmacokinetics
and/or tissue penetration of brain tissue and/or brain abscess?
Question 2: What is the best surgical approach in terms of
outcome in managing bacterial brain abscesses?
3.2. Literature search and study selection
A MEDLINE/EMBASE search was made.
3.3. Research strategy question 1
‘Brain abscess/therapy’ [MAJR] AND ‘anti-bacterial agents’
[MAJR] AND ((‘1’ [PDat]: ‘2008/06/30’ [PDat])): retrieved 114, of
which 11 were reviews. ‘Brain abscess/drug therapy’ [MeSH] AND
‘brain abscess/surgery’ [MeSH] NOT tuberculosis (no limits):
retrieved 194, of which 28 were reviews. ‘Brain abscess/drug
therapy’ [MAJR] AND ‘brain abscess/surgery’ [MAJR] NOT tubercu-
losis: retrieved 17, of which ﬁve were reviews. This was limited to
the last 30 years and written in English.
3.4. Inclusion criteria question 1
Patients of all ages, with non-tuberculosis bacterial cerebral
abscesses of any origin (spontaneous or post-surgical), singular or
multiple, of any size, occurring in the last 30 years were included.
 Operations: any treatment to cure bacterial cerebral abscess.
 Comparison: any comparison between antibiotic regimes vs. any
surgical approach used to treat bacterial cerebral abscess.
 Outcome: survival, follow-up results, quality of life, time for the
reduction of abscesses, frequency of recurrence.
 Design: publications in English, randomized controlled trials
(RCTs), and any comparative designs declared to be so or which
are shown from research within the last 30 years (Fig. 1).
3.5. Research strategy question 1a
‘Brain abscess/therapy’ [MAJR] AND ‘anti-bacterial agents’
[MAJR] NOT tuberculosis (chronological limit: from 01/01/1978
to 31/08/2008): retrieved 95, of which nine were reviews. ((‘Brain’
OR ‘intra-cerebral’ OR ‘intracranial’ OR ‘cerebral’) AND ‘abscess’)
AND ‘therapy’ AND ‘anti-bacterial agents’ NOT tuberculosis (within
the last 30 years in English): retrieved 342, of which 74 were
reviews; linezolid and brain abscess 15; linezolid and ventriculitis[(Figure_1)TD$FIG]
[(Figure_4)TD$FIG][(Figure_2)TD$FIG]
Figure 2. Studies included in the ﬁnal analysis.
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daptomycin and ventriculitis 3; tigecycline and brain abscess 0.
3.6. Inclusion criteria question 1a
Patients of any age with non-tuberculosis bacterial cerebral
abscesses of any origin (spontaneous or post-surgical), singular or
multiple, of any size, occurring in the last 30 years were included.
 Operations: any treatment to cure bacterial cerebral abscess.
 Comparison: any comparison between antibiotic regimes vs. any
surgical approach used to treat bacterial cerebral abscess.
 Outcome: survival, follow-up results, quality of life, time for the
reduction of abscesses, frequency of recurrence.
 Design: publications in English, RCTs, and any comparative
designs declared to be so or which are shown from research
within the last 30 years (Fig. 2).
3.7. Research strategy question 1b
‘Anti-bacterial agents’ AND ‘pharmacokinetics’ AND (‘cerebro-
spinal ﬂuid’ OR ‘brain abscess’) NOT tuberculosis (within the last
30 years and in English): retrieved 95, of which nine were reviews.
(‘brain abscess’ [MeSH Terms]) AND (‘antibiotic penetration’):
retrieved 23, of which seven were reviews.
3.8. Inclusion criteria question 1b
Patients of any age with non-tuberculosis bacterial cerebral
abscess of any origin (spontaneous or post-surgical), singular or
multiple, of any size, occurring in the last 30 years were included.
 Operations: any treatment to cure bacterial cerebral abscess.
 Comparison: any comparison between pharmacokinetics of any
antibiotics on brain tissue or cerebral abscess.
 Outcome: therapeutic concentration evaluated on cerebral tissue
or cerebral abscess.
 Design: publications in English, RCTs, and any comparative
designs declared to be so or which are shown from research
(Fig. 3).
[(Figure_3)TD$FIG]Figure 3. Studies included3.9. Research strategy question 2
‘Brain abscess/surgery’ [MAJR] AND ((‘1’ [PDat]: ‘2008/06/30’
[PDat])): retrieved 392, of which 35 were reviews. ‘Brain abscess’
AND ‘surgery’ AND ((‘2008/07/01’ [PDat]: ‘2008/09/20’ [PDat])):
retrieved nine, of which two were reviews. ‘Brain abscess/surgery’
[MAJR] NOT tuberculosis: retrieved 199, of which 29were reviews.
((‘Brain’ OR ‘intra-cerebral’ OR ‘intracranial’ OR ‘cerebral’) AND
‘abscess’) AND (‘surgical treatment’ OR ‘operative surgical proce-
dures’) NOT tuberculosis: retrieved seven.
3.10. Inclusion criteria question 2
Patients of any age with non-tuberculosis bacterial cerebral
abscess of any origin (spontaneous or post-surgical), singular or
multiple, of any size, occurring in the last 30 years were included.
 Operations: any surgical treatment to cure bacterial cerebral
abscess.
 Comparison: any comparison between any surgical approach
used to treat cerebral abscess.
 Outcome: survival, follow-up results, quality of life, time for the
reduction of abscesses, frequency of recurrence.
 Design: publications in English, RCTs, and any comparative
designs declared to be so or which are shown from research
within the last 30 years (Fig. 4).
3.11. Classiﬁcation and evaluation of selected evidence
No RCTs were found. For questions 1 (antibiotic therapy
compared with surgical therapy) and 2 (comparisons between
different surgical approaches), data were present only in retro-
spective cohort studies or descriptive case series planned to
underline the clinical characteristics of people with cerebral
abscess and to determine factors related to the outcome. A matrix
Figure 4. Studies included in the ﬁnal analysis.in the ﬁnal analysis.
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using the Newcastle–Ottawa Quality Assessment Scale for case-
control studies and longitudinal cohorts and retrospective studies
with comparative evaluations. The original data from case studies
weremade homogeneous using a predeﬁned format, both for cases
reports and series of reported cases. For questions 1a (comparison
between different antibiotic regimens) and 1b (comparison
between pharmacokinetics/pharmacodynamics of different anti-
biotics), no comparative studies were found. For the ﬁrst question,
we chose to consider papers where the antibiotic regimens were
reported and the impact on outcome was clear. For the second
question, we looked at papers where the antibiotic penetration
into the brain tissue or brain pus was investigated.
We were not able to precisely separate research for each of
these categories given that none of the categories were treated
prospectively or in a controlledmanner.We only had retrospective
cohorts of case series, and any information on individual cases was
within these case studies. Therefore, these publications were often
used to answer different types of questions.
In the discussion section, to assign the strength to the level of
the recommendations, a methodology adapted from GRADE
Working Group was applied. The details of the methodology are
reported in this supplement.9
4. Results
4.1. Question 1: Which patients with bacterial brain abscesses can be
managed safely using only medical treatment?
Bacterial brain abscess is essentially a surgical pathology and
most cases arise from neurosurgery.
In many of these case series, a variable number of patients were
treated successfully with medical therapy alone. Xiao et al.6
retrospectively analyzed themedical records of patients with brain
abscess treated over a period of 17 years (1986–2002) to determine
the factors related to outcome. One hundred and ﬁfteen patients
(65%) underwent surgical decompression of the abscess, while 63
(35%) received only medical treatment (38 had relatively small
lesions and 25 had a larger abscess, with signiﬁcant surgical risk).
Unfavorable outcomes included death (25%), vegetative status
(5%), and responding but remaining totally dependent during daily
life (8%). In the surgically treated patients, 27–38% of patients had
an unfavorable outcome, depending on the type of surgical
approach, whereas 41% (n = 26) of medically treated patients
died. Considering patients with small lesions, 24/38 (65%) patients
had favorable outcomes comparedwith only 3/25 (12%) patients at
signiﬁcant surgical risk. Multivariate analysis showed that the
factors predictive of outcome were: initial Glasgow Coma Score
(GCS), immunodeﬁciency, and absence of underlying diseases, but
not type of treatment.
Tseng and Tseng10 retrospectively analyzed themedical records
of 142 patients with intracranial abscess observed between 1986
and 2004 to identify clinical, biological, and therapeutic char-
acteristics important for outcome. The cases had the same
structure as the previous study and the time-scale was largely
similar. The authors found no association between outcome and
treatment type. Six out of 20 (30%) medically treated patients had
an unfavorable outcome compared with 31/122 (25.4%) surgically
treated patients. Multivariate logistic regression conﬁrmed that
beingmale, having a GCS>12, and being sepsis-free were themain
factors for a favorable outcome.
Hakan et al.11 reviewed 96 consecutive cases treated over 13
years (1988–2001) in order to determine the current character-
istics and the other factors important for the outcome of brain
abscess. Surgery was performed in 90% of patients (lesions were
aspirated in 84% and excised in 16%), whereas 10 patients (10%)were treated non-surgically. The choice of treatment was based on
the size of the abscess (8–29 mm in the group treatedwithmedical
therapy alone comparedwith 20–35 mm in the excision group and
30–69 mm in the aspiration group). The recovery ratios were 90%,
85%, and 47%, respectively. The initial neurological grade
(GCS < 12), the size of the abscess, meningismus, high fever
(>38.5 8C), and leukocytosis (>20  109/l), were the factorsmostly
inﬂuencing mortality and sequelae.
In documenting changes in the characteristics and manage-
ment of brain abscesses, Mampalan and Rosemblum12 reviewed
107 consecutive cases at the University of California, San Francisco
over 17 years (1970–1986). Ninety-six of these patients were
treated: 79 surgically (46 excision, 33 aspiration) and 17 with
medical therapy alone. The mortality and reoperation rates in the
three treatment groups were not signiﬁcantly different. The
duration of intravenous (iv) antibiotic therapy was shorter in
the excision group than in the aspiration and non-surgical groups.
Factors inﬂuencing outcome were the initial neurological grade
and the size of the abscess. The average diameter of non-surgically
treated abscesses was 2 cm (range 0.75–4.5 cm). Both patients
who failed medical therapy had abscesses larger than 3 cm in
diameter.
Over a period of 4 years (1984–1987), Leys et al.8 selected a
population of consecutively treated patients with similar initial
prognoses in order to compare the results of the three procedures:
medical treatment alone, aspiration, and excision. The choice of
treatment was at the discretion of the neurologist or neurosurgeon
in charge of the patient and based on perceived best procedure.
From the initial 79 cases, patients with multiple focal intracranial
infections (21 cases), focal infections located in the posterior fossa
(six cases), and lesions smaller than 1 cm or larger than 5 cm (four
patients) were withdrawn; 56 cases with a single hemisphere focal
intracranial infection of 1–5 cm were retained. There were no
statistical differences in number of deaths (after months 1, 3, and
12) or in social outcome among the three groups. Sequelae
(seizures and focal deﬁcits) were more severe in surgically treated
patients, and in these patients the causative organism was more
often isolated and the hospital stay was shorter.
Qureshi et al.13 selected 66 patients with brain abscess treated
over 12 years (1987–1998) to clarify the clinical status of brain
abscess and to assess predictors of mortality in these patients.
Management was conservative in 27 (42%) patients and surgical in
38 (58%). Logistic regression identiﬁed a distantmetastatic focus as
the sole independent predictor of mortality. Conservative treat-
ment, coma at presentation, duration of symptoms <2 weeks,
multiple abscesses, steroid therapy, age, and sex were not
predictive factors.
In order to report their experience of managing brain abscesses
in Taiwan, Wong et al.3 considered 83 patients of different ages,
ranging from neonates to those aged 15 years. Fifteen (18.1%)
patients were treated with medical therapy alone, whereas 68
(81.9%)were treatedwith antibiotics and surgery. Deathswere 40%
and 14.7%, respectively, and patients lost to follow-up 33.3% and
19.1%, respectively; however no statistical analysis of the
differences was made.
Carpenter et al.2 reported 49 cases of cerebral abscess; all
except ﬁve were treated surgically. Surgical intervention was
considered unnecessary (criteria not reported) in these ﬁve
patients, all of whom recovered well.
To compare clinical, electroencephalographic, and computed
tomography (CT) results of different therapeutic approaches
(excision, puncture, and medical treatment), over a period of 3
years Russeaux et al.14 selected 31 cases of hemispheric brain
abscess. The patients were divided into three groups according to
their treatment, and on the basis of their initial neurological status
were divided into four stages of increasing gravity. No apparent
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three groups. Only 1/15 patients in the non-surgically treated
group died; the survivors completely recovered or had moderate
disabilities. There were no deaths among the four patients treated
by puncture and antibiotic therapy and all patients totally
recovered, whereas among the patients treated by excision, 2/12
died and two had important neurological deﬁcits. The differences
in terms of outcome were more deﬁnite between the groups
treated medically and by puncture, but no statistical analysis was
made to compare these differences. The medically treated patients
were in poor initial neurological condition, but the abscesses were
smaller. The criteria for the choice of the different therapeutic
approaches were not clear.
Schliamser et al.15 reviewed 54 consecutive adult patients with
cerebral abscess. Thirty-three patients was treated by surgery plus
antibiotics and 14 bymedical treatment alone; seven patients died
as a result of missed diagnosis, the abscess was found at autopsy.
Indications for conservative therapy were multiple abscesses, the
site in a high-risk region of the brain, and concomitant
endocarditis. Twenty-three of the 33 (69.6%) patients who
underwent surgery died or had severe sequelae vs. 6/14 (42.8%)
of patients treated with medical therapy alone. No statistical
analysis for the different therapies was made.
Ferriero et al.16 reviewed 17 patients, aged 4months to 18 years,
ofwhomeightwere treatedmedically andnine received surgery. All
but one patient treated with medical therapy alone fully recovered
(one patient died of causes not related to the cerebral abscess),
whereas of the patients treated surgically, one died and four had
neurological deﬁcits. The authors concluded that antibiotic therapy
without surgical intervention is the treatment of choice for patients
with positive identiﬁcation of organisms. Nevertheless, medically
treated patients were in better initial condition, the criteria for the
choice of the different therapeutic approaches were not reported,
and a statistical analysis of the differences was not made.
Chun et al.17 reviewed 45 consecutive patients admitted to
eight hospitals in Louisville, to evaluate the efﬁcacy of various
diagnostic and therapeutic approaches. Forty-one patients were
treated for brain abscess, of whom 31 (75.6%) received both
surgical and antimicrobial therapy and 10 (24.4%) antimicrobial
therapy alone. Of the surgically treated patients, 10/31 (32.2%) died
and 11/31 (35.4%) had moderate or severe neurological sequelae
compared with 4/10 (40%) and 1/10 (10%) patients treated with
antibiotics alone. The higher mortality was signiﬁcantly associated
with older age, male sex, altered sensorium on admission, and a
pulmonary source as a predisposing factor, but not with surgical
operation, the type of surgery, or the appropriateness of antibiotic
treatment in terms of dosage, route of administration and
sensitivity of the organism. The patients received a total of 27
different antibiotics, and although patient characteristics on
admission were similar, the rationale for treating with antibiotics
alone was not clearly stated.
4.2. Question 1a:What is the efﬁcacy in terms of outcome, tolerability,
cost/efﬁciency, and quality of life of the different antibiotic regimens
used in the treatment of bacterial cerebral abscesses?
Often antibiotic therapy is started empirically, before a possible
surgical operation and in cases ofmedical treatment alone,without
a microbiological diagnosis, and is also continued empirically. The
ﬁrst element to consider in the choice of antibiotic regimen is
therefore the etiology of the bacterial cerebral abscess.
4.3. Bacteriology of the cerebral abscess
The bacterial etiology of cerebral abscess is largely dependent
on the origin of the abscess itself. Many series of cases measure thefrequency of bacterial isolation, but not all correlate the isolation
with the origin of the abscess. Generally, themost frequent isolated
microorganisms are Gram-positive cocci (e.g., streptococci and
staphylococci) and anaerobes, even if Gram-negative bacteria are
also present. Often there is mixed bacterial ﬂora (Table 1). In
particular, post-traumatic and post-surgical abscesses frequently
have a staphylococcal etiology, although Gram-negative aerobic
bacilli have also been reported.18,19
Dashti et al.18 retrospectively reviewed the cases of post-
operative infection after cranial surgery over 10 years (1997–2007)
focusing on patients who required a re-operation to control the
infection, to determine the rate of these infections. They
considered 16 540 cranial operations performed by 25 neurosur-
geons, including 82 (0.5%) corresponding to 50 patients, performed
to treat a post-operative infection. Brain abscesses accounted for
10 (20%) of these infections. The most common organism was
Staphylococcus spp (10 methicillin-susceptible Staphylococcus
aureus (MSSA), two methicillin-resistant Staphylococcus aureus
(MRSA), six coagulase-negative staphylococci (CoNS)), isolated
from 18 (36%) patients.
McLelland and Hall20 wanted to deﬁnitively establish the
incidence of post-operative CNS infections in patients undergoing
neurosurgical procedures and the potential risk factors. They
analyzed 2111 elective procedures performed by a single surgeon
between February 1991 and December 2005. Of the 1587 cranial
operations, 14 (0.8%) were complicated by infection. The most
common causative organism was S. aureus (six cases, 42.9%); none
of these strains were methicillin-resistant.
Tekko¨k and Erbengy21 cultured four S. aureus isolates from 11
post-traumatic brain abscesses.
In a case series of 96 children with cerebral abscess, Domingo
and Peter22 reported 26 cases of implantation abscesses secondary
to trauma where the most common organism isolated was S.
aureus.
Schliamser et al.15 isolated 19 staphylococci (12 S. aureus, seven
S. epidermidis) from 24 adults with post-traumatic cerebral
abscesses.
Sichizya et al.19 reviewed 121 patients treated at the Groote-
Schuur Hospital (Cape Town, South Africa) of whom 49% had
abscesses associated with implantation by trauma. S. aureus, CoNS
and b-hemolytic streptococci were the three most prevalent
pathogens. The periodontal/sinusitis origin of abscess was
frequently associated with Streptococcus milleri.19,22
Otogenic abscesses almost invariably yield a mixed ﬂora,
including anaerobes and various streptococci, but also Enterobac-
teriaceae (especially Proteus mirabilis) and/or Pseudomonas aeru-
ginosa.7,19,20,23,24
The organisms predominantly associated with metastatic or
cryptogenic abscesses are Streptococcus spp. In these cases,
abscesses frequently complicate episodes of septicemia, in which
etiological agents can be isolated from blood cultures.2,7,12,13,23
Table 1 lists the principle microorganisms isolated from
cerebral abscesses in the different case series.
In 2007 The Cochrane Collaboration25 published a review to
evaluate the effectiveness of antibiotic regimens for treating brain
abscess in people with cyanotic congenital heart disease. The
studies included were all RCTs that reported clinically meaningful
outcomes and presented results on intention to treat, irrespective
of blinding, publication status, and language. Therewere no studies
that met the inclusion criteria.
In 2000, the ‘Infection in Neurosurgery Working Party’ of the
British Society of Antimicrobial Chemotherapy (BSAC)7 published a
review providing recommendations on the management of
bacterial brain abscesses based on information from the review
process together with the experience and knowledge of its
members. The recommendations suggested a combination of
Table 1
Frequency of the principle microorganisms isolated from cerebral abscess from different case series
Microorganism Hirsh 198369 Schliamser 198815 Jansson 200426 Wong 19893 Seydoux 199250 Tekko¨k 199221 Lunardi 199348 Domingo 199423
Gram-positive bacteria 13
Streptococci 6 10 19 9 18 5 40 12
Staphylococcus aureus 1 19 1 2 3 19 16 17
CoNS 1 9 2 2 1
Other Enterococci 5
Gram-negative bacilli 12
Proteus spp 2 5 12
Klebsiella spp 1 1 3
Enterobacter spp 1 1
Escherichia coli 4
Serratia spp
Pseudomonas spp 1 5
Anaerobes 2
Peptostreptococcus 1 11 4 2 3 5 3
Bacteroides spp 1 7 14 6
Fusobacterium spp 3 14
Clostridium spp 1
Bacillus fragilis 3 5
Microorganism Kao 200370 Sichizya 200519 Xiao 20056 Hakan 200611 Menhaz 200649 Tseng 200610 Carpenter 20072 Cavus¸oglu 20084
Gram-positive bacteria 27
Streptococci 7 46 14 18 11 12 8
Staphylococcus aureus 2 24 5 17 8 6 MRSA
CoNS 14 1 1 3 MRSE
Other Enterococci 6 7 S. pneumoniae
Gram-negative bacilli 21
Proteus spp 4 13 2 12
Klebsiella spp 1 4 3 2 1
Enterobacter spp 7 2 2 1
Escherichia coli 6 1 1
Serratia spp 1 2
Pseudomonas spp 3 1 3 1 2
Anaerobes 24 8
Peptostreptococcus 2 4 5 10 1 2
Bacteroides spp 2 7 4 4
Fusobacterium spp 1 1 2
Clostridium spp 8 1
Propionibacterium spp 4 3
CoNS, coagulase-negative staphylococci; MRSA, methicillin-resistant Staphylococcus aureus; MRSE, methicillin-resistant Staphylococcus epidermidis.
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empirical therapy for patients with sinugenic or odontogenic brain
abscesses, a combination of ampicillin, metronidazole and either
ceftazidime or gentamicin for those with otogenic abscesses,
ﬂucloxacillin or third-generation cephalosporin for abscesses
secondary to trauma and, depending on the presumptive source,
benzylpenicillin or third-generation cephalosporin metronidazole
for patients with metastatic abscesses.
Jansson et al.26 retrospectively evaluated 66 patients treated
with cefotaxime over a period of 10 years using a prospectively
designed protocol. Sixty-two of these patients received additional
metronidazole and 53 underwent surgery. The dose of cefotaxime
and metronidazole recommended for adults with normal renal
function was 3 g three times daily and 1 g once daily, respectively,
after a loading dose of 4 g and 1.5 g, respectively. The duration of
treatment was left to the discretion of the physician. Reversible
adverse reactions, which occurred in 57% of patients, were the
most common reasons for withdrawing the cefotaxime. The
median duration of parenteral antibiotic treatment was 36 days in
patients treatedwith total excision, 36.5 days in those treatedwith
sub-total excision, 41 days in aspiration, 22 days in evacuation of
subdural empyema, and 46 days in patients treated with
antibiotics alone. The total durations of antibiotic treatment,
including oral administration performed in 71% of patients, were
46, 114, 84.5, 49, and 84 days, respectively. In 25 cultures from
patients treated for 3 days there was growth in 21 (84%)
compared with 7/22 (32%) from patients treated for >3 days
(p < 0.001).Sjo¨lin et al.27 studied 15 consecutive patients with cerebral
abscess over a period of 3 years (1986–1989), treated with
cefotaxime (3 g three times daily) plus metronidazole (0.5 g three
times daily) and surgical excision, to prospectively study clinical
and bacteriological outcomes. All patients survived and there was
no recurrence within 1 year. The duration of cefotaxime plus
metronidazole therapy was 22  6 days. Eleven of 15 patients
received subsequent oral regimens, whichwasmainly trimethoprim–
sulfamethoxazole-based. Adverse reversible side effects leading to
the discontinuation of therapy were observed in nine (60%) patients.
Cultures of specimens from three of nine patients treated for >24 h
were positive compared with positive cultures for all six specimens
obtained from patients treated for <24 h (p = 0.017); anaerobic
bacteria were isolated from two of three patients given two doses of
metronidazole or fewer compared with none of 12 patients given
three doses or more.
Kowlessar et al.23 described 22 patients observed over a period
of 8 years (1996–2004) in order to evaluate the efﬁcacy of
cefotaxime in themanagement of brain abscess caused by S. milleri.
The patients were divided into two groups: group A (15 patients
with GCS >12) received 2 g cefotaxime 4 times daily plus
metronidazole 1.5 mg 3 times daily iv for 4 weeks. Intravenous
benzylpenicillin was added in four patients and in ﬁve patients the
therapy with oral antibiotics was prolonged based on neurological
deterioration and incomplete resolution on imaging. Group B (four
patients with GCS <12 and three patients with GCS = 14, but
considered at risk of clinical deterioration) received cefotaxime six
times a day plus metronidazole and rifampin 600 mg twice daily
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benzylpenicillin and three had additional switch therapy. All
patients underwent surgery. Eighteen patients (82%) had a good
outcome after 6 months, resuming normal life or having minor
deﬁcits. There were no signiﬁcant differences in terms of outcome
between the two groups.
Akova et al.28 examined the efﬁcacy and safety of sulbactam/
ampicillin (50 and 100 mg/kg/day, respectively in four divided
doses) in 21 patients with a diagnosis of cerebral abscess enrolled
over a period of 4 years (1987–1991). Sixteen patients underwent
surgery (drainage by burr hole in 12 patients and exploration by
craniotomy in four patients), whereas ﬁve patients were treated
with antibiotics alone. Three patients died due to causes not
related to their infections. The overall success rate was 81% and did
not differ in patients treated with or without surgery. The mean
duration of antibiotic therapy was 48  10 days, and four patients
(19%) experienced mild reversible side effects that recovered after
temporary cessation of the antibiotic.
Rau et al.29 reviewed 33 cases that occurred over a period of 14
years (1986–1999) of which 23 were community-acquired and 10
were hospital-acquired (mainly post-neurosurgical) to improve
the therapeutic strategies available for the management of brain
abscesses caused by aerobic Gram-negative bacilli. The most
prevalent pathogen isolatedwas Klebsiella pneumoniae followed by
P. aeruginosa, Escherichia coli and Proteus spp, all isolated bacteria
were susceptible to third-generation cephalosporins and chlor-
amphenicol. Twenty-six patients were treated surgically and with
antibiotic therapy, while seven received antibiotics alone. Seven
patients died with an overall mortality of 21%, 6/16 patients
treated with penicillin plus chloramphenicol and one medicated
with piperacillin died compared to none of the 16 patients treated
with various cephalosporins.
To compare aspiration, excision, and antibiotic treatment alone,
Leys et al.8 treated patients with ceftriaxone (2–3 g iv), peﬂoxacin
(800 mg intramuscularly) and metronidazole (1.5 g iv), except
when these antibiotics failed to be effective in vitro against the
causative organisms. In these cases, thiophenicol (3–4.5 g iv) or
ampicillin (8–12 g iv) or trimethoprim–sulfamethoxazole (320–
1600 mg) were used.
In a review of 121 patients with surgically treated cerebral
abscesses observed before 1996, Sichizya et al.19 reported the use
of empirical antibiotic regimens including benzylpenicillin,
chloramphenicol, andmetronidazole, replaced by third-generation
cephalosporins with cloxacillin and metronidazole following the
advent of third-generation cephalosporins. These regimens were
changed according to bacterial isolation and sensitivity test results.
The patients in the study received an average of 15 and 19 days of
parenteral antibiotics for excision and aspiration, respectively. The
duration of antibiotic therapy was determined by the decrease in
level of the erythrocyte sedimentation rate (ESR) and C-reactive
protein (CRP), the diameter of the abscess on follow-up CT scans,
and the temperature charts of the patient, but speciﬁc indicators
were not reported.
In more recently treated cases, Tayfun (2006)30 principally
reported the use of third-generation cephalosporins and anti-
anaerobic antibiotics. In cases of MRSA, vancomycin was used.
Carpenter et al.2 reported cefotaxime and metronidazole as the
most commonly used antibiotics in 37/49 (73%) patients,
sometimes with the addition of benzylpenicillin, vancomycin,
ﬂucloxacillin, or gentamicin.
Javad et al.31 reported a case of multiple brain abscesses in a
renal transplant recipient that developed two days after a
nephrectomy of the left transplanted kidney. No aspiration of
the abscess was performed due to the patient’s poor clinical
condition. P. aeruginosa resistant to ciproﬂoxacinwas isolated from
the pleural effusion and assumed to be the cause of the brainabscess. Although sensitivity testing was not performed for
cefepime, imipenem, and piperacillin/tazobactam, the patient
was successfully treated with piperacillin/tazobactam 2.25 mg
three times daily continued for 2 months.
Ntziora and Falagas32 reviewed 42 cases where linezolid was
used for the treatment of patients with CNS infections, of whom 11
(26%) had cerebral abscesses (excluding three patients with
mycobacterial abscesses and one with aspergillosis, and including
one patient with cerebritis). All patients were treated following
either failure or toxicity of the ﬁrst-line therapy. Of these, nine
were cured or recovered considerably, onewas stable, and one died
due to the abscess. Collateral effects were reported in seven of the
42 patients and in two of these the treatment had to be suspended
(severe anemia and myelosuppression).
Malacarne et al.33 reported two cases of CNS infection due to
methicillin-resistant S. epidermidis (MRSE) treated with linezolid.
The ﬁrst case, a woman with ventriculitis with a ventricular
catheter, was successfully treated with linezolid concentrations in
the cerebrospinal ﬂuid (CSF) higher than the minimum inhibitory
concentration (MIC), agreeing with other reports.34 In the second
case, a man with post-traumatic cerebral abscess, despite the high
serum peak level of linezolid, it was not found in the CSF after 5
days, or in cerebral tissue removed 14 days after therapy.
Unexplainably, the drug was measured in the CSF at a concentra-
tion greater than the MIC value for MRSE at day 15 and the patient
clearly improved clinically.
4.4. Question 1b: Which antibiotics have the best pharmacokinetics
and/or tissue penetration of brain and/or brain abscess?
Sjo¨lin et al.35 assessed the penetration of cefotaxime and of its
active metabolite desacetyl cefotaxime in brain abscesses in eight
patients. After an initial 4 g loading dose of cefotaxime, a
maintenance dose of 3 g every 8 h (q8 h) was administered. After
a variable number of drug doses (one to seven), brain abscess
samples were collected 4–9 h after the last drug administration
before surgery. Mean  standard deviation (SD) cefotaxime and
desacetyl cefotaxime concentrations in brain tissue were higher than
in plasma (2.1  1.6 mg/l vs. 2.0  1.0 mg/l and 4.0  2.2 mg/l vs.
3.9  1.8 mg/l, respectively). These values, which were higher than
theMIC of the bacterial isolates (range 0.02–2.0 mg/l), led the authors
to suggest that both cefotaxime and its active metabolite may well
penetrate the brain abscess.
Green et al.36 investigated the penetration of ceftazidime into
intra-cranial abscesses in nine patients. Variable daily drug
dosages were used (0.5–2 g q8 h); the number of drug doses
before tissue sampling was not indicated. Brain abscess samples
were collected 1–9 h after the last drug administration before
surgery. Ceftazidime concentrations in brain tissue ranged
between 2.7 and 27.0 mg/l. Since no comparison with simulta-
neously collected plasma samples was performed, no deﬁnitive
conclusion on the tissue penetration rate was reported. These
values, which were higher than the MIC50 of most microorganisms
commonly involved, led the authors to suggest that ceftazidime
may penetrate brain abscesses.
In a small clinical series of 15 brain abscess patients treated
with imipenem 1 g every 6–8 h, drug levels were determined in
three patients who underwent abscess aspiration.37 Brain pus
trough levels ranged between 0.1 and 0.4 mg/l with a brain pus-to-
plasma trough concentration ratio ranging between 0.05 and 0.13.
These values were considered above the MIC90 of several Gram-
positive and anaerobic bacterial isolates.
Mindermann et al.38 assessed the penetration of fusidic acid
into human brain tumors and/or into the perifocal cortex in six
neurosurgical patients after a single 500 mg iv dose. Brain tissue
samples were collected 50–135 min after drug administration
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between <0.25 and 9.04 mg/l with a brain tissue-to-plasma
concentration ratio of 0.01–0.1. These values were on average
several-fold higher than the MIC of staphylococci, so that the
authors suggested that fusidic acid may well penetrate brain
tissue.
4.5. Question 2: What is the best surgical approach in terms of
outcome in managing bacterial brain abscess?
Mampalan and Rosemblum12 in their review of 102 cases over a
period of 17 years, grouped patients according to treatment. Forty-
six underwent craniotomy and the excision of the brain abscess
and 33 underwent aspiration of a single lesion through a
craniotomy or burr hole; however the reasons for the different
approaches were not reported. Mortality (8.7% in the excision
group and 6.1% in the aspiration group) and reoperation rates (8.7%
and 15.2%, respectively) in the two groups were not statistically
different. Long-term follow-up was available for 48 patients.
Seizures occurred in 10% of patients without signiﬁcant differences
between the treatment groups.
Xiao et al. 6 retrospectively analyzing 178 patients over a period
of 17 years, reported surgical decompression of the abscess in 115
patients (65%). The initial procedures included drainage in 73
patients, aspiration in 13 (who underwent stereotactic techniques
because the abscess was either deep or small), and excision in 29.
Thirteen patients required one or more reoperations, 10 of whom
were in the drainage group. There were no signiﬁcant differences
in percentage of favorable outcome in the three groups: 73%, 72%,
and 62%, respectively. However, the mortality rate was lowest in
patients undergoing excision (3.4%), followed by drainage (18%)
and aspiration (31%).
Tseng and Tseng10 retrospectively considered 142 patients of
whom 122 (85.9%) underwent surgical treatment. 74 had
drainages by craniotomy, 14 had excision and 34 had stereotactic
aspirations. The drainage or excision by craniotomy was
performed for larger (> 2.5 cm) or superﬁcial brain abscesses.
The stereotactic aspirations were performed in patients with a
brain stem abscess, a small and deep seated abscess, or multiple
small abscesses. There was no association between favorable
outcome and treatment modalities.
Padney et al.,39 to investigate whether cerebral abscesses are
better managed by excision or aspiration, evaluated the manage-
ment of cerebral abscesses in 82 children over a period of 10 years
(1995–2004). Primary excisionwas performed in 66 patients (60%)
and aspiration in 16 patients (40%). The indications for primary
aspiration included a poorly formed abscess wall, a poor GCS at
presentation, rapid neurological deterioration, and severe anemia
requiring preoperative correction. In ﬁve patients who underwent
aspiration as ﬁrst treatment, the residual abscess was electively
excised. There were no deaths among patients who underwent
excision (four in the aspiration group; p = 0.001), fewer recur-
rences (12.6% vs. 54.5%; p = 0.003), and less need of repeated
procedures (9.8% vs. 45.4%; p = 0.008). However, patients who
underwent primary aspiration were in a poorer condition at
presentation.
Renier et al.,40 to correlate clinical, bacteriological, radiological,
and therapeutic features of neonatal brain abscesses in order to
identify possible prognostic criteria, considered 30 newborn
infants with cerebral abscesses treated over a period of 12 years
(1975–1987). The abscesses were treated with aspiration and
antibiotics in 25 cases and by antibiotics alone in ﬁve. The
indications for the different approacheswere not reported. A series
of 36 older children with brain abscess treated in the same
institution over the same period was considered to detect
differences in prognostic factors between the two groups. Earlyaspiration (100% survival rate in children aspirated before day 30
of life vs. 70% in children aspirated later than day 30 of life) of the
abscess was the only signiﬁcant factor inﬂuencing survival in this
series. Early aspiration togetherwith the absence of initial seizures,
sterile CSF, and normal ventricles on CT scan, appeared to be
factors leading to a better prognosis in terms of epilepsy and
mental sequelae.
Mamelak et al. 41 developed an algorithmic rationale and a
course of treatment for patients with multiple brain abscesses,
analyzing 16 patients with multiple brain abscesses from a total of
131 patients with brain abscess over 16 years (1976–1992). All
abscesses >2.5 cm in diameter or causing signiﬁcant mass effect
were excised or stereotactically aspirated. The choice of surgical
approach was not critical, even though the stereotactic approach
may have been useful for deep-seated lesions or multiple
hemispheric abscesses, while aspiration by craniotomy or excision
in cases of posterior fossa abscesses. Abscesses in the cerebritis
phase could be approached with medical treatment alone. When a
surgical approach was chosen, antibiotics were started after
withdrawal of pus and were continued for a minimum of 6 weeks
(typically 8 weeks). Using this systematic approach, the mortality
rate was 6%, while the morbidity of further and multiple
procedures was not observed.
Kocherry et al.,42 to evaluate the efﬁcacy of stereotactic
aspiration in managing deep-seated and/or intracranial abscesses
in the eloquent region, reported 22 cases treated over a period of 6
years (1995–2001). All patients received iv antibiotics for a
minimum of 4 weeks or longer, and in cases of multiple abscesses
(ﬁve patients) the larger ones were treated with stereotactic
aspiration while the smaller ones were medically treated. There
were no deaths; early recurrence requiring repeated aspiration
was diagnosed in ﬁve patients, minor hemorrhages were noted in
three patients, and one patient developed ventriculitis requiring a
shunt insertion, but there were no late recurrences.
Moss et al.43 reviewed 54 consecutive cases observed between
1958 and 1987 to compare changes in surgical treatment and
outcome of cerebral abscesses in children. Forty-eight children had
surgical operations (12 aspirations, 14 open evacuations, and 22
resections). The mortality rate in the aspiration group was twice
that of the evacuation or resection group (17.7% and 9%,
respectively), but no indications for the different approaches were
reported and no stratiﬁcation of groups or statistical analyses was
made.
Ers¸ain et al.44 reviewed 44 consecutive patients aged between 1
month and 16 years. Total excision was accomplished in 22
patients, three patients underwent needle aspiration, and drainage
was performed in 13, but indications for choosing the different
surgical approaches were not reported. The mortality rates
associated with the different modes of surgical treatment were
not signiﬁcantly different from each other.
Cavus¸oglu et al.,4 in their review of 51 patients, reported
completed excision for 10 patients, stereotactic aspiration for nine,
and aspiration from a single burr hole for the remaining 32
patients. Indications for stereotactic aspiration were multiple or
deep-seated abscesses or abscesses located in the eloquent areas of
the brain. Post-traumatic, cerebral, post-operative, or poor
response to repetitive aspiration abscesses underwent complete
excision. No comparisons were made between the different
surgical approaches, but the choice of surgical approach was
considered not critical and should be dictated by surgeon
preference and the ability of the patient to tolerate each type of
surgical procedure.
Srinivasan et al.45 reported 37 cases of capsulated brain abscess
treated with elective aspiration through a burr hole and intra-
cavity application of antibiotics on alternative days until two
consecutive negative aspirations were obtained. A combination of
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tion was in good initial neurological condition with 30 cases
(81.1%) having a GCS of 12–15; the mortality rate was 2.7% and no
new neurological deﬁcits occurred after surgery.
Gupta et al.46 reviewed 80 cases of brain abscess of which 74
were treated surgically: 28 underwent aspiration followed by
excision, 25 were treated by aspiration(s) alone, and 21 by direct
excision. Only one patient who underwent excision died compared
with eight and three managed with repeated aspiration and
medical treatment alone, respectively. Nevertheless, no indica-
tions for the different approaches and no stratiﬁcations for GCS
level at presentation into the different groups of treatment were
reported.
Barlas et al.47 reported 21 patients who underwent stereotactic
surgical drainage and an 8-week iv antibiotic regimen. Eleven of
these 21 patients had multiple (from two to nine) abscesses, all
deep-seated. Four patients had an abscess>2.5 cm in diameter, the
largest being 4.4 cm. Except for three patients who had residual
mild hemiparesis and one patient recovering from ataxia, all
patients irrespective of small or large size, solitary or multiple,
superﬁcial or deep-seated abscesses, made a complete neurologi-
cal recovery.
Huda et al. 24 reported 40 patientswith Gram-negative bacillary
brain abscesses managed by total excision (n = 31), aspiration
(n = 5), and aspiration followed by excision (n = 4), but no
comparison in terms of outcome was made between groups.
Domingo and Peter22 reported the presentation, treatment, and
outcome of 98 children with cerebral abscesses. Ninety-eight
percent of patients were treated surgically, of whom 92%
underwent burr hole aspiration,while 8%with cerebellar abscesses
underwent surgical excision. A further 12% had a secondary
excision because of the failure of aspiration. Themortality rate was
correlated to initial GCS (70% for patients with GCS<8) supporting
the importance of early diagnosis, but no differences in outcome
were correlated with the different surgical approaches.
Lunardi et al.48 considered 80 patients with surgically managed
cerebral abscesses observed from 1953 to 1989. Twenty-one
patients underwent aspiration (10 either CT- or ultrasound-
guided). Twenty percent of patients died within 30 days of
operation and in 16.2% of patients, death was attributable to
surgical complications. During follow-up, another 22.2% of
patients died and in all cases death was due to progression of
the primary illness. The mortality rate was related to clinical
grading on admission, but not to the type of surgical approach (20%
of deaths in the excision group compared to 19.9% in the aspiration
group). No deaths occurred in patients treated stereotactically.
Menhaz et al.,49 investigating the clinical proﬁle, microbiology,
and outcome of children with cerebral abscess with underlying
congenital heart disease compared with other predisposing
conditions, reported 30 children, 37% of whom had congenital
heart disease, who underwent surgical treatment of their cerebral
abscess. All patients were initially managed by drainage via burr
hole, but six were subsequently excised. Five (16%) children died
soon after abscess drainage. The overall bad prognostic features
included deranged sensorium, midline shift, and cerebral edema;
the latter two were found to complicate children with congenital
heart disease more than the non-cardiac group.
Seydoux and Francioli50 reviewed 36 of 39 patients with
cerebral abscess managed surgically. In 26 patients the lesions
were excised, while in 10 they were aspirated. The surgical
technique used did not depend on the location, but on the length of
the lesions. Excision was attempted for superﬁcial lesions and
stereotactic aspiration for the deeper ones. Twelve out of 39
patients died or had severe sequelae, but apart from the patient’s
initial clinical impairment, none of the factors analyzed, including
the type of surgery performed, inﬂuenced the outcome.Brindon and Hardwidge51 reported 15 patients with cerebral
abscesses, seven of whom underwent aspiration as the primary
procedure, while eight had total or partial excision. No signiﬁcant
differences between the two groups could be found comparing
mortality rate, number of complications, and residual symptoms.
Tekko¨k and Erbengy,21 in their retrospective review of 130 cases
of cerebral abscesses in children over a period of 21 years, reported a
mortality rate of 14.5% in patients who underwent aspiration and
16.2% in patients who had total or partial excision. The difference
was not statistically signiﬁcant. No statistically signiﬁcant contri-
bution to mortality rate was found either for location or number of
abscesses and underlying congenital heart disease.
Aydin et al.52 aiming to determine factors affecting the
prognosis, reviewed 42 patients with cerebral abscesses treated
over a period of 8 years (1979–1987). Twenty-four patients
underwent drainage, while 18 were managed by excision, but no
indications were reported for choosing the different surgical
techniques. No statistically signiﬁcant differences were found in
mortality for age, sex, and different surgical approach, whereas
mortality was inﬂuenced by the duration of the complaints and
preoperative conditions.
Bhand53 reviewed 82 patients with cerebral abscess treated
over a period of 5 years (1998–2003). Surgical management
consisted of aspiration in 38% of cases, while aspiration along with
excision was carried out in the remaining 62% of patients.
Indications for aspiration alone were deep-seated, less developed
capsular formation of the abscess and cyanotic heart disease origin.
Excisional removal of brain abscess was done in cases where the
abscess was superﬁcial and with well-developed capsule forma-
tion, or where the etiology was of traumatic or otogenic origin. The
overall mortality rate was 22% (18 cases), 12 in the excision group
(related to ventriculitis (six cases), septicemia (three cases), and
postoperative hemorrhage (three cases)) and six patients in the
aspiration group. Patients who underwent excision fared well on
GCS, but there was no stratiﬁcations of cases for clinical
seriousness at presentation.
Yildizhan et al.1 retrospectively investigated 41 cases of
cerebral abscesses. Seventeen patients underwent aspiration,
while 24 patients were managed by excision, but the criteria for
choosing the different surgical approaches were not reported. The
overallmortality ratewas 36.5%,with 58.8% in the aspiration group
and 20.8% in the excision group. The mortality rate was highly
related to the preoperative level of consciousness, with all deaths
in patients who had a GCS<10, but no differences were reported in
the number of patients with poor GCS between the two groups
managed by different surgical techniques.
5. From the evidence to the recommendations
5.1. Question 1: Which patients with bacterial brain abscess can be
managed safely using only medical treatment?
5.1.1. Discussion
The studies considered were all retrospective, not randomized,
and not designed to detect differences. The case studies often
included long periods of time with possible changes in risk factors,
sensitivity and diagnostic methods, the sensitivity of microorgan-
isms, and availability and choice of antibiotics. The antibiotic
therapy was often not indicated and the choice of therapeutic
approach in most cases was not made on clear and explicit
grounds. Therewere therefore no references thatwould allowus to
choose patients with cerebral abscess for medical treatment alone,
even if a variable number of patients were treated successfully,
thus avoiding surgery.
So, without certain criteria, the choice of the treatment should
consider the advantages and disadvantages of each of the separate
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reduced morbidity linked to surgical operations (particularly
cerebral edema,47,49 hemorrhage complications,5,42,47–49 and the
possible spread of the infection17,41,48). The reduction in late
sequelae mentioned by certain authors14 (GRADE score 1) needs to
be conﬁrmed in wider case studies with an adequate follow-up.
However, we need to consider that surgery is not only a
therapeutic option, but also allows conﬁrmation of the diagnosis
and the sampling of material formicrobiological diagnosis, and, for
excision in particular, often reduces the duration of antibiotic
treatment3,12,14,16 (GRADE scores 1, 2, 1, 1, respectively), reducing
the toxicity risk26,27,53–55 (GRADE score 1, 2, 1, 1, 1, respectively),
the hospitalization rate, and the frequency of controls8 (GRADE
score 2).
Common data in most of the case studies examined were the
factors that most inﬂuenced the ﬁnal outcome, being the initial
neurological state and the size of the abscess6,10,11,12,13,26,41
(GRADE score 1, 1, 1, 2, 1, 2, 2, respectively), although other
factors such as gender10,17 (GRADE score 1 for both), etiology,
diagnosis of sepsis10,11 (GRADE score 1 for both), and origin of the
abscess13 (GRADE score 1) have also been reported.Recommendations
The best candidates formedical treatment appear to be those
with a small abscess (<2.5 cm), in good initial clinical condition
(GCS >12), and for whom the etiology is well-known
(microorganism isolated from material other than the abscess
pus) [C].
Medical treatment can also be used in the therapy of
multiple abscesses, after surgery of abscesses >2.5 cm or
surgery of abscesses that cause a mass effect, or in patients at
serious risk of operation even if in these, the ﬁnal decision must
consider that the prognosis is often bad in any case [D].
In agreement with the algorithms proposed by Mamelak
et al.41 and Xiao et al.,6 in patients treated solely medically,
surgery should be reconsidered when the clinical condition is
worsening or without clinical and radiological improvements
within 1–2 weeks [C].
The choice of patients for a medical approach must be made
on an individual basis, considering the patient’s characteristics
and the experience and consideration of the surgeon, and trying
to ﬁnd a balance between the risk of the surgical approach and
the risk of not achieving a microbiological diagnosis, increasing
the hospitalization time and the duration of antibiotic
treatment, with related toxicity [D].5.2. Question 1a:What is the efﬁcacy in terms of outcome, tolerability,
cost/efﬁciency, and quality of life of the different antibiotic regimens
used to treat bacterial cerebral abscesses?
5.2.1. Discussion
There have been no RCTs that have evaluated the efﬁcacy of
different antibiotic therapies. There has also been no comparison of
different antibiotic treatments. Inmanyseries of cases, the antibiotic
therapywasnot shownorwas incomplete for themoleculeused, the
type of administration, and the administration time. Few case
studies have looked at the toxicity of antibiotic treatment.
Recommendations on initial empirical therapy made by the
BSAC7 (GRADE score 2), include the microbiology of the abscess,
the data concerning penetration of the various antibiotics into the
CNS, and some clinical data and experience of the members of the
working group.Since the publication of these recommendations (2000), the
most common association of antibiotics has been metronidazo-
le + third-generation cephalosporin, particularly cefotaxime, but
also ceftriaxone. Metronidazole + cefotaxime has been seen to be
efﬁcient in empirical treatment and that aimed at cerebral
abscesses, but is also highly toxic, mainly causing rashes with or
without itching, leucopenia, high temperatures, and increased
transaminase26,27 (GRADE score 2 and 1, respectively). Undesired
effects appear after the ﬁrst week of therapy or later and often lead
to the discontinuation of treatment. This, also considering that data
on the toxicity of antibiotic treatment is often not shown, should be
kept in consideration when the therapeutic approach is chosen,
given that surgery, particularly excision, could considerably reduce
the overall exposure time to antibiotics3,12,14,17 (GRADE score 1, 2,
1, 1, respectively).
Other iv antibiotics used in treating cerebral abscesses, often
within different associations, include: penicillin2,12,13,17,19,23
(GRADE score 1, 2, 1, 1, 1, 1, respectively), chlorampheni-
col12,13,17,19,29 (GRADE score 2, 1, 1, 1, 1, respectively), ampicil-
lin8,12,17 (GRADE score 2, 2, 1, respectively), ampicillin/sulbactam28
(GRADE score 1), peﬂoxacin8 (GRADE score 2), nafcillin12 (GRADE
score 2), cloxacillin19 (GRADE score 1), ﬂucloxacillin2 (GRADE score
1), vancomycin2,11,12 (GRADE score 1, 1, 2, respectively), amino-
glycoside2,12 (GRADE score 1, 2, respectively), piperacillin and
tazobactam31 (GRADE score 1), and linezolid31 (GRADE score 1).
However, there are no concrete data comparing their efﬁcacy and
tolerability.
In particular the use of linezolid for therapy of CNS infections has
been reported. There are, however, few reports on the successful
treatment of meningitis and ventriculitis from difﬁcult Gram-
positive bacteria56,57 (GRADE score 1 for both) even in neonates58
(GRADE score 1) or cerebral abscesses secondary to meningitis54,55
(GRADE score 1 for both). In cerebral abscesses of other origins
where there is even less experience, alongside therapeutic success32
(GRADE score 1), other more contradictory, but unexplainable
results have also been reported54 (GRADE score 1).
5.3. Question 1b: Which antibiotics have the best pharmacokinetics
and/or tissue penetration of brain tissue and/or brain abscess?
5.3.1. Discussion
The infrequency of intracranial infection has precluded
comparative pharmacokinetic studies of antimicrobials, and only
in a minority of cases has the penetration of antimicrobials into
brain abscess and/or brain tissue been assessed. This is mainly
related to methodological issues in tissue sampling; direct
measurement of drug concentrations at this body site is usually
very difﬁcult to perform.
Since in all of these pharmacokinetic studies, drug concentra-
tions of antimicrobials in brain abscess and/or brain tissue were
simply assessed in a single tissue sample at variable times from
drug administration without a complete pharmacokinetic proﬁle,
as a general rule, it is almost impossible to draw any deﬁnitive
conclusions on penetration rates of antimicrobials due to the
hysteresis phenomenon. Accordingly, from a pharmacokinetic
point of view, in the absence of any deﬁnitive evidence about
which antibiotics have the best pharmacokinetics in brain tissue
and/or brain abscess, it could be helpful to consider some general
rules when choosing a drug to treat brain abscess35,59 (GRADE
score 1 for both).
Drug penetration into brain tissue may be impaired by the
anatomical integrity of the blood–brain barrier. It is expected that
this impairment may be greater for hydrophilic compounds,
namely b-lactams and aminoglycosides, but especially for
glycopeptides, which have a very high molecular weight.
Accordingly, larger than standard doses of antibiotics are
Recommendations
There is insufﬁcient evidence to make speciﬁc recommenda-
tions for antibacterial treatment of cerebral abscess. However,
on the basis of the limited clinical data and of pharmacokinetic/
pharmacodynamic (PK/PD) considerations, some drug choices
and schedule regimens may be suggested (Table 2) [D].
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barriers in these cases59 (GRADE score 1), even if drug diffusion
across the blood–brain barrier could be enhanced in the brain areas
affected by inﬂammation60 (GRADE score 1).
Conversely, lipophilic compounds, namely ﬂuoroquinolones,
rifampin, metronidazole, and oxazolidinones are expected to
achieve much higher penetration rates even in the presence of
undamaged barriers. Although the physiological properties of the
blood–brain barrier and the blood–CSF barrier are distinct,
additional pharmacokinetic information about the penetration
of antimicrobials into the CNS could be extrapolated from studies
carried out in neurosurgical patients with external ventriculost-
omy who are unaffected by meningitis. Indeed, in these situations,
penetration of systemically administered antimicrobials into the
CSF could be similar, since it may occur only through undamaged
barriers61 (GRADE score 1).
Various studies have documented that optimal exposure in the
CSF with lipophilic agents such as rifampin62 (GRADE score 1),
linezolid34 (GRADE score 1), levoﬂoxacin63 (GRADE score 1), and
moxiﬂoxacin64 (GRADE score 1), may also be achieved with
standard dosages. However, for hydrophilic antimicrobials such as
third-generation cephalosporins65 (GRADE score 1), meropenem66
(GRADE score 1), and vancomycin67,68 (GRADE score 1 and 2,
respectively), larger than standard dosages may be necessary.
5.4. Antibiotic therapy of cerebral abscess
5.4.1. Start of the antibiotic therapy
Frequently, given the possible critical nature of the patients, the
antibiotic therapy is started before surgery, when this occurs. Data
on sterilization of cerebral abscesses are both fragmented and not
controlled, however the probability of identifying the pathogen in
the pus culture decreases with the administration time of the
antibiotics. For metronidazole associated with third-generation
cephalosporin, the probability of having a positive culture from the
pus taken surgically reduces considerably during the ﬁrst three
days of therapy26,27 (GRADE score 2 and 1, respectively).27Recommendations
The sample from the abscess should be made without
antibiotic therapy or, at least within not more than 3 days of the
start of therapy [D].
Recommendations
An advised overall period of 4–6 weeks is considered
prudent for surgically treated abscesses. Six to eight weeks is
advised for iv treatment of abscesses treated solely medically
and in the case of multiple abscesses when larger ones are
treated surgically [C].5.4.2. Choice of the drug
Theoretically, the ideal antibiotic to treat cerebral abscess
shouldbe that active in themicrobial ﬂora,with thebest penetration
of the abscess pus and with the best safety proﬁle especially in
long-term administration, possibly administrated orally.
In post-trauma and post-surgical abscesses, the empirical
therapy should consider the possible presence of staphylococci
and Gram-negative rods. In post-surgical ones in particular, there
is the possibility of methicillin resistance for staphylococci and
variable resistance according to the ecology of Gram-negative rods.
Therefore, particularly in post-surgical forms, the possibility of
using new molecules seems to be attractive, both given their
spectrum of action and their ease of administration (e.g., linezolid,
daptomycin, tigecycline). There has been no clinical experience
with tigecycline and daptomycin, while for linezolid there have
been some clinical evaluations of efﬁcacy32,54 (GRADE score 1 for
both), nevertheless with unexplainable conﬂicting results in one
case33 (GRADE score 1), and demonstration of good kinetics34
(GRADE score 1). Experience is scarce and activity data should bevalidated in wider studies. However, linezolid could be a valid
alternative in cases of allergy to b-lactam antibiotics or to
sulfonamides or in the case of failure of a previously administered
treatment. It should be considered in the front line against difﬁcult
Gram-positive bacteria, considering the high dosages of glycopep-
tides, especially vancomycin67,68 (GRADE score 2 and 1, respec-
tively), needed for efﬁcient concentrations in CNS infections.
Obviously there are no concrete data on the toxicity of linezolid in
this pathology, but this is common practice for all molecules with
these indications. Where toxicity data are shown (e.g., cefotax-
ime), these underline the high risk of collateral effects that could
lead to the suspension of treatment26,27 (GRADE score 2 and 1,
respectively).5.4.3. Duration of treatment
No study has comparatively evaluated how the duration of the
iv treatment and/or the overall duration of antibiotic therapy
inﬂuence outcome. Often, these parameters are not shown, or are
simply described without evaluating the correlation with the ﬁnal
outcome. The duration of the antibiotic treatment has therefore
been considered a largely empirical choice. Where therapy time
of intravenously administered antibiotics is shown, it is usually
not less than 4 weeks4,12,23,26–28,41,42,47,53 (GRADE score 1, 2, 1, 1,
2, 1, 2, 1, 1, 1, respectively). Where shorter times are reported,19
(GRADE score 1) reference is made to other parameters such as the
reduction of CRP (C-reactive protein), the size of the abscess, and
the thermal curve. However, quantitative indicators are not
mentioned (the amount of CRP reduction and the size of the
abscess that permits the iv therapy to be stopped safely).
Without parameters that can safely evaluate the endovenous
therapy time, we agree with the BSAC recommendations7 (GRADE
score 2).5.4.4. Oral therapy
Often, antibiotic treatment is prolonged orally after the initial iv
treatment19,27 (GRADE score 1 for both), but in these cases the
drug/s used are not reported. Many of the recommended iv drugs
(e.g., third-generation cephalosporin, oxacillin, vancomycin, car-
bapenem, and piperacillin/tazobactam) do not have indications for
oral use or dosages needed for cerebral abscesses cannot be
reached using this method. Therefore, the choice to change to an
orally administered treatment appears often to be arbitrary and
the outcome difﬁcult to quantify.
Drugs that could be used orally include: trimethoprim–
sulfamethoxazole, ﬂuoroquinolone, amoxicillin/clavulanic acid,
Table 2
Suggested drug choices and scheduled regimens.
Post-trauma abscess Post-surgical abscess Abscesses from paranasal
sinuses, middle ear and of
dental origin
Metastatic or cryptogenic abscessesb
Cefotaxime 2g q6h
+
metronidazole 500 q8h

rifampin 10 mg/kg q24h
Linezolid 600mg q12h
or
vancomycin 40–60 mg/kg/24-hourly as
a continuous infusion (adjusted for creatinine clearance)
after a 15 mg/kg loading dose or 10–15 mg/kg q6h
aiming for serum levels of 15–25 mg/l
plus rifampin 10 mg/kg q24h
+
meropenem 1.5 g q6h or 2g q8h
or
piperacillin/tazobactam 4.5 g q6h
Metronidazole 500mg q8h
+
cefotaxime 2g q6h
or
piperacillin/tazobactam
4.5 g q6ha
Cefotaxime 2g q6h

metronidazole 500mg q8h
or
ampicillin/sulbactam 100/50 mg/kg q6h
a If Pseudomonas aeruginosa is suspected.
b In the case of a positive blood culture in the presence of endocarditis, use therapy suggested for endocarditis.
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reported indications in published research include ampicillin/
sulbactam28 (GRADE score 1), metronidazole27 (GRADE score 1),
trimethoprim–sulfamethoxazole27,44 (GRADE score 1 for both),
rifampin23 (GRADE score 1), and linezolid58 (GRADE score 1).Recommendations
We do not believe there is sufﬁcient information to give
recommendations for orally administered antibiotics. However,
the choice of completing treatment using this method should to
reserved for those cases where the bacteria have been isolated
and there is a sensitivity proﬁle, using drugs with good
penetration into the infection site [D].
Recommendations
The choice of the type of surgical approach does not appear
to be critical in determining outcome and should take into
account the preference and the ability of the surgeon, as well as
the ability of the patient to tolerate each procedure. The initial
clinical condition of the patient and the speed of the therapeutic
operation, including surgery, appear to be the more decisive
factors for the ﬁnal outcome [D].
Recurrent indications for aspiration by stereotactic approach
are as follows: deep-seated or small abscesses or those located
in eloquent areas,multiple hemispheric abscesses, patientswho
are poor candidates for general anesthesia [D].
Drainage by craniotomy or craniectomy or excision are used
more often in superﬁcial abscesses and those found in the
posterior cranial fossa [D]. Furthermore, excision is often used
in post-traumatic, postoperative patients and those with a poor
response to repetitive aspiration [D].5.5. Question 2: What is the best surgical approach in terms of
outcome in managing bacterial brain abscess?
5.5.1. Discussion
Surgical options in cerebral abscess management include
complete or partial excision of the abscess or drainage. The latter
can be carried out with a burr hole or craniotomy or using
stereotactic aspiration.
In very general terms, we can say that the advantages of
stereotactic aspiration are as follows: the simplicity of the
operation, the possibility of using the technique during cerebri-
tis39,41 (GRADE score 1 and 2, respectively), the small degree of
trauma involved, and the possibility of not resorting to narcosis.
The principle disadvantages are however the frequent need for
multiple operations6,39,46 (GRADE score 1 for each) and the
possibility of failure requiring rectiﬁcation with excision, which
has a higher degree of complete success4,19,39,49 (GRADE score 1 for
each).
There have been no controlled prospective studies comparing
the various surgical approaches in homogeneous populations of
patients with cerebral abscesses, neither in terms of efﬁcacy nor in
terms of morbidity. The compared data come from studies of
retrospective cohorts or descriptive series of cases, which are
certainly not suitable for measuring any differences.
Often, indications that lead to different types of surgery are not
shown and the follow-up periods are different in the different
studies or even within the same case series. Outcome is often
considered only in terms of mortality, while long-term outcome is
either not shown or only partially so. The case series are often overa long period of time and are collected in very different
geographical areas with different epidemiologies and different
diagnostic support and technologies.
Apart from these comments:
 Outcome principally in terms of mortality, but also long-term
outcome, is affected above all by the initial conditions of the
patient rather than the type of surgery1,22,48,49,50 (GRADE score 1
for each).
 When evaluated40 (GRADE score 1), even if in a special
population such as neonates and compared with a different
population, the speed with which the operation is made, rather
than the type of operation, is the factor that most affects the ﬁnal
condition of these patients.
 Recurrent indications for aspiration by stereotactic approach are
as follows: deep-seated or small abscesses of those located in
eloquent areas, multiple hemispheric abscesses, patients who
are poor candidates for general anesthesia4,5,39,41,42,47,53 (GRADE
score 1 for each).
 Drainage by craniotomy or craniectomy or excision is used more
often in superﬁcial abscesses and those found in the posterior
cranial fossa4,10,22,39,41,50 (GRADE score 1, 1, 1, 1, 2, 1,
respectively). Furthermore, excision is often used in post-
traumatic, postoperative patients and thosewith a poor response
to repetitive aspiration4,22,53 (GRADE score 1, 1, 1, respectively).
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